These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24168232)

  • 1. Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols.
    Kim TH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    Int J Urol; 2014 Apr; 21(4):377-81. PubMed ID: 24168232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center.
    Lee DH; Jung HB; Lee SH; Rha KH; Choi YD; Hong SJ; Yang SC; Chung BH
    Jpn J Clin Oncol; 2012 Nov; 42(11):1079-85. PubMed ID: 22988037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols.
    Tsang CF; Tsu JH; Lai TC; Wong KW; Ho BS; Ng AT; Ma WK; Yiu MK
    Hong Kong Med J; 2017 Dec; 23(6):609-15. PubMed ID: 29026057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men.
    Yamada Y; Sakamoto S; Sazuka T; Goto Y; Kawamura K; Imamoto T; Nihei N; Suzuki H; Akakura K; Ichikawa T
    Int J Urol; 2016 Jan; 23(1):49-54. PubMed ID: 26450768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient selection and pathological outcomes using currently available active surveillance criteria.
    El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
    BJU Int; 2013 Aug; 112(4):471-7. PubMed ID: 23746382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort.
    Smaldone MC; Cowan JE; Carroll PR; Davies BJ
    J Urol; 2010 Jan; 183(1):138-43. PubMed ID: 19913808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
    Jeon HG; Yoo JH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM; Ferrari M; Brooks JD; Chung BI
    PLoS One; 2017; 12(11):e0186026. PubMed ID: 29136019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.
    Kang DI; Jang TL; Jeong J; Choi EY; Johnson K; Lee DH; Kim WJ; Kim IY
    Asian J Androl; 2011 Nov; 13(6):838-41. PubMed ID: 21785442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
    Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
    BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy does not adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance.
    Pietzak EJ; Kabarriti AE; Mucksavage P; Bavaria T; Van Arsdalen K; Malkowicz SB; Wein AJ; Guzzo TJ
    Urology; 2014 Dec; 84(6):1442-7. PubMed ID: 25288572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols.
    Komisarenko M; Timilshina N; Richard PO; Alibhai SM; Hamilton R; Kulkarni G; Zlotta A; Fleshner N; Finelli A
    J Urol; 2016 Dec; 196(6):1645-1650. PubMed ID: 27350077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
    Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
    Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.
    Busch J; Magheli A; Leva N; Ferrari M; Kramer J; Klopf C; Kempkensteffen C; Miller K; Brooks JD; Gonzalgo ML
    BJU Int; 2014 Oct; 114(4):517-21. PubMed ID: 24112652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostatectomy pathology findings in an active surveillance population.
    Ramirez-Backhaus M; Iborra I; Gomez-Ferrer A; Rubio-Briones J
    Arch Esp Urol; 2014 Jun; 67(5):431-9. PubMed ID: 24914842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of the Disparity Between Biopsy and Pathologic Gleason Score After Radical Prostatectomy in Clinical Candidates for Active Surveillance According to the Royal Marsden Criteria.
    Jo JK; Hong SK; Byun SS; Lee SE; Lee S; Oh JJ
    Clin Genitourin Cancer; 2016 Aug; 14(4):e329-33. PubMed ID: 26935997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological outcomes of candidates for active surveillance of prostate cancer.
    Conti SL; Dall'era M; Fradet V; Cowan JE; Simko J; Carroll PR
    J Urol; 2009 Apr; 181(4):1628-33; discussion 1633-4. PubMed ID: 19233388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive report on prostate cancer misclassification by 16 currently used low-risk and active surveillance criteria.
    Palisaar JR; Noldus J; Löppenberg B; von Bodman C; Sommerer F; Eggert T
    BJU Int; 2012 Sep; 110(6 Pt B):E172-81. PubMed ID: 22314081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.